Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "InflaRx" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about InflaRx for you to read. Along with our medical data and news we also list InflaRx Clinical Trials, which are updated daily. BioPortfolio also has a large database of InflaRx Companies for you to search.
InflaRx N.V, a clinical─stage biopharmaceutical company, announced the approval of an Investigational Medicinal Product Dossier (IMPD) from the European regulatory authorities, allowing InflaRx to initiate a phase II
InflaRx has completed patient enrolment in a Phase IIb clinical trial to evaluate IFX-1 in the treatment of moderate to...Read More... The post InflaRx completes enrolment in hidradenitis suppurativa trial appeared first on Drug Development Technology.
InflaRx has dosed the first patient in a Phase II trial to examine the safety and efficacy of IFX-1 for...Read More... The post InflaRx doses first patient in Phase II trial of IFX-1 appeared first on Drug Development Technology.
$IFRX Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa https://finance.yahoo.com/news/inflarx-announces-presentation-clinical-data-120000758.html …
SummaryInflaRx NV InflaRx is a clinicalstage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications. Its pipeline products includes IFX1 and IFX2. InflaRx ope...
SummaryInflaRx NV InflaRx is a developer of therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications. Its products comprise IFX1 and IFX2. The company undertakes various research and development progr...
Continues Development of Neuroscience Portfolio, Aiming to Bring New Therapies to Patients Company Prepared to Move Lead Asset to Phase 3 in Parkinson’s Disease in 2019 Bain Capital, LP and Pfizer Inc. (NYSE: PFE) today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutic...